216 related articles for article (PubMed ID: 26275901)
1. The impact of HPV vaccination on future cervical screening: a simulation study of two birth cohorts in Denmark.
Hestbech MS; Lynge E; Kragstrup J; Siersma V; Vazquez-Prada Baillet M; Brodersen J
BMJ Open; 2015 Aug; 5(8):e007921. PubMed ID: 26275901
[TBL] [Abstract][Full Text] [Related]
2. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
3. Clinical performance of primary HPV screening cut-off for colposcopy referrals in HPV-vaccinated cohort: Observational study.
Beecroft M; Gurumurthy M; Cruickshank ME
BJOG; 2023 Jan; 130(2):210-213. PubMed ID: 36054732
[TBL] [Abstract][Full Text] [Related]
4. Effects of numerical information on intention to participate in cervical screening among women offered HPV vaccination: a randomised study.
Hestbech MS; Gyrd-Hansen D; Kragstrup J; Siersma V; Brodersen J
Scand J Prim Health Care; 2016 Dec; 34(4):401-419. PubMed ID: 27845597
[TBL] [Abstract][Full Text] [Related]
5. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
[TBL] [Abstract][Full Text] [Related]
7. Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines.
Almonte M; Sasieni P; Cuzick J
Best Pract Res Clin Obstet Gynaecol; 2011 Oct; 25(5):617-29. PubMed ID: 21683657
[TBL] [Abstract][Full Text] [Related]
8. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
9. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.
Tota J; Mahmud SM; Ferenczy A; Coutlée F; Franco EL
Sex Health; 2010 Sep; 7(3):376-82. PubMed ID: 20719230
[TBL] [Abstract][Full Text] [Related]
10. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
[TBL] [Abstract][Full Text] [Related]
11. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
12. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change.
Franco EL; Mahmud SM; Tota J; Ferenczy A; Coutlée F
Arch Med Res; 2009 Aug; 40(6):478-85. PubMed ID: 19853188
[TBL] [Abstract][Full Text] [Related]
13. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
[TBL] [Abstract][Full Text] [Related]
14. Will vaccinated women attend cervical screening? A population based survey of human papillomavirus vaccination and cervical screening among young women in Victoria, Australia.
Brotherton JM; Mullins RM
Cancer Epidemiol; 2012 Jun; 36(3):298-302. PubMed ID: 22204834
[TBL] [Abstract][Full Text] [Related]
15. Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia.
Hall MT; Simms KT; Lew JB; Smith MA; Saville M; Canfell K
PLoS One; 2018; 13(2):e0185332. PubMed ID: 29444073
[TBL] [Abstract][Full Text] [Related]
16. HPV testing and vaccination in Europe.
Leeson SC; Alibegashvili T; Arbyn M; Bergeron C; Carriero C; Mergui JL; Nieminen P; Prendiville W; Redman CW; Rieck GC; Quaas J; Petry KU
J Low Genit Tract Dis; 2014 Jan; 18(1):61-9. PubMed ID: 23774078
[TBL] [Abstract][Full Text] [Related]
17. Test Performance of Cervical Cytology Among Adults With vs Without Human Papillomavirus Vaccination.
Teoh D; Nam G; Aase DA; Russell R; Melton GB; Kulasingam S; Vogel RI
JAMA Netw Open; 2022 May; 5(5):e2214020. PubMed ID: 35612854
[TBL] [Abstract][Full Text] [Related]
18. How does HPV vaccination status relate to risk perceptions and intention to participate in cervical screening? a survey study.
Hestbech MS; Gyrd-Hansen D; Kragstrup J; Siersma V; Brodersen J
BMC Public Health; 2016 Aug; 15():708. PubMed ID: 27488178
[TBL] [Abstract][Full Text] [Related]
19. What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination.
Lynge E; Antilla A; Arbyn M; Segnan N; Ronco G
Eur J Cancer; 2009 Oct; 45(15):2714-21. PubMed ID: 19695870
[TBL] [Abstract][Full Text] [Related]
20. Impact of human papillomavirus age-related prevalence and vaccination levels on interpretation of cervical screening modalities: a modelling study.
Grimes DR
BMJ Open; 2024 Feb; 14(2):e078551. PubMed ID: 38309749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
